Compass Therapeutics (CMPX) Operating Leases (2021 - 2026)
Compass Therapeutics (CMPX) posted Operating Leases of $8.4 million for Q1 2026, down 4.66% sequentially from $8.8 million in Q4 2025, and up 34.22% YoY from $6.3 million in Q1 2025.
Compass Therapeutics (CMPX) Operating Leases (2021 - 2026) Analysis & Trends
Compass Therapeutics has reported Operating Leases for 6 years, with the latest figure at $8.4 million in Q1 2026.
- Quarterly Operating Leases rose 34.22% year-over-year to $8.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.4 million (up 34.22% YoY) and the FY2025 annual result came in at $8.8 million, up 40.23% from the prior year.
- Operating Leases retreated to $8.4 million in Q1 2026 per CMPX's latest filing, from $8.8 million in the prior quarter.
- Over five years, Operating Leases peaked at $9.8 million in Q3 2025 and troughed at $536000.0 in Q4 2023.
- A 5-year average of $4.7 million and a median of $3.0 million in 2022 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2023 and 2024: Operating Leases sank 70.84% in 2023, then surged 1074.63% in 2024.
- Over 5 years, Operating Leases stood at $1.8 million in 2022, then sank by 70.84% to $536000.0 in 2023, then soared by 1074.63% to $6.3 million in 2024, then jumped by 40.23% to $8.8 million in 2025, then slipped by 4.66% to $8.4 million in 2026.
- According to Business Quant data, Operating Leases over the past three periods registered $8.4 million, $8.8 million, and $9.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Compass Therapeutics | 405.20 Mn | 405.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.63 Mn |
| Mar 31, 2026 | 8.42 Mn |
| Dec 31, 2025 | 8.83 Mn |
| Sep 30, 2025 | 9.83 Mn |
| Jun 30, 2025 | 9.63 Mn |
| Mar 31, 2025 | 6.27 Mn |
| Dec 31, 2024 | 6.30 Mn |
| Sep 30, 2024 | 6.32 Mn |
| Mar 31, 2024 | 1.41 Mn |
| Dec 31, 2023 | 536,000.00 |
| Sep 30, 2023 | 2.04 Mn |
| Jun 30, 2023 | 2.34 Mn |
| Mar 31, 2023 | 2.64 Mn |
| Dec 31, 2022 | 1.84 Mn |
| Sep 30, 2022 | 3.22 Mn |
| Jun 30, 2022 | 2.44 Mn |
| Mar 31, 2022 | 2.74 Mn |
| Dec 31, 2021 | 3.05 Mn |
| Sep 30, 2021 | 3.33 Mn |
| Mar 31, 2021 | 3.88 Mn |